Doxorubicin pathways

Lal, 2010, Pharmacogenetics of target genes across doxorubicin disposition pathway: a review., Curr Drug Metab, 11, 115, 10.2174/138920010791110890

Simunek, 2009, Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron., Pharmacol Rep, 61, 154, 10.1016/S1734-1140(09)70018-0

Mordente, 2009, New developments in anthracycline-induced cardiotoxicity., Curr Med Chem, 16, 1656, 10.2174/092986709788186228

Carvalho, 2009, Doxorubicin: the good, the bad and the ugly effect., Curr Med Chem, 16, 3267, 10.2174/092986709788803312

Arcamone, 1969, Adriamycin, 14-hydroxydaunomycin: a new antitumor antibiotic from S. peucetius var. caesius.., Biotechnol Bioeng, 11, 1101, 10.1002/bit.260110607

Cortes-Funes, 2007, Role of anthracyclines in the era of targeted therapy., Cardiovasc Toxicol, 7, 56, 10.1007/s12012-007-0015-3

Swain, 2003, Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials., Cancer, 97, 2869, 10.1002/cncr.11407

Gewirtz, 1999, A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin., Biochem Pharmacol, 57, 727, 10.1016/S0006-2952(98)00307-4

Doroshow, 1986, Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones., Proc Natl Acad Sci U S A, 83, 4514, 10.1073/pnas.83.12.4514

Pawlowska, 2003, Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase., Oncol Res, 13, 245, 10.3727/096504003108748294

Fogli, 2004, The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage., FASEB J, 18, 664, 10.1096/fj.03-0724rev

Tewey, 1984, Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase-II., Science, 226, 466, 10.1126/science.6093249

Oakman, 2009, The role of topoisomerase-IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients., Cancer Treat Rev, 35, 662, 10.1016/j.ctrv.2009.08.006

Fedier, 2001, Resistance to topoisomerase poisons due to loss of DNA mismatch repair., Int J Cancer, 93, 571, 10.1002/ijc.1356

Robles, 1999, Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death., Oncogene, 18, 4681, 10.1038/sj.onc.1202862

Minotti, 2004, Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms., Methods Enzymol, 378, 340, 10.1016/S0076-6879(04)78025-8

Wallace, 2007, Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis., Cardiovasc Toxicol, 7, 101, 10.1007/s12012-007-0008-2

Swain, 1997, Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer., J Clin Oncol, 15, 1318, 10.1200/JCO.1997.15.4.1318

Wojnowski, 2005, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity., Circulation, 112, 3754, 10.1161/CIRCULATIONAHA.105.576850

Rossi, 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia, 23, 1118, 10.1038/leu.2008.398

Minotti, 1998, The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitaseiron regulatory protein-1 in cytosolic fractions from human myocardium., FASEB J, 12, 541, 10.1096/fasebj.12.7.541

Olson, 1988, Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol., Proc Natl Acad Sci U S A, 85, 3585, 10.1073/pnas.85.10.3585

Weinstein, 2000, Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice., J Pharmacol Exp Ther, 294, 396

Clementi, 2003, Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria., Anticancer Res, 23, 2445

Hasinoff, 2003, The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin., Free Radic Biol Med, 35, 1469, 10.1016/j.freeradbiomed.2003.08.005

Lyu, 2007, Topoisomerase-IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane., Cancer Res, 67, 8839, 10.1158/0008-5472.CAN-07-1649

Van Dalen, 2010, Different anthracycline derivates for reducing cardiotoxicity in cancer patients., Cochrane Database Syst Rev, 5, CD005006

Robert, 2007, Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls., Cell Biol Toxicol, 23, 27, 10.1007/s10565-006-0142-9

Platel, 1999, Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model., Anti-cancer Drugs, 10, 671, 10.1097/00001813-199908000-00007

Neef, 1988, An interaction between cytostatic and anticonvulsant drugs., Clin Pharmacol Ther, 43, 372, 10.1038/clpt.1988.45

Cusack, 1988, Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit., Cancer Chemother Pharmacol, 22, 294, 10.1007/BF00254234

Colombo, 1994, Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats., J Pharmacol Exp Ther, 269, 22

Singhal, 2010, Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer., Int J Cancer, 126, 1327, 10.1002/ijc.24767

Gianni, 2007, Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes., Cardiovasc Toxicol, 7, 67, 10.1007/s12012-007-0013-5

Kaye, 1985, Tumour cell resistance to anthracyclines: a review., Cancer Chemother Pharmacol, 14, 96, 10.1007/BF00434344

Germann, 1996, P-glycoprotein: a mediator of multidrug resistance in tumour cells., Eur J Cancer, 32A, 927, 10.1016/0959-8049(96)00057-3

Cole, 1992, Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line., Science, 258, 1650, 10.1126/science.1360704

Young, 2001, Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels., Clin Cancer Res, 7, 1798

Singhal, 2003, Role of RLIP76 in lung cancer doxorubicin resistance: I. The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistances in lung cancer cells., Int J Oncol, 22, 365

Burgess, 2008, Topoisomerase levels determine chemotherapy response in vitro and in vivo., Proc Natl Acad Sci U S A, 105, 9053, 10.1073/pnas.0803513105

Pritchard, 2008, HER-2 and topoisomerase II as predictors of response to chemotherapy., J Clin Oncol, 26, 736, 10.1200/JCO.2007.15.4716

Jacquet, 1990, Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters., Cancer Chemother Pharmacol, 27, 219, 10.1007/BF00685716

Torti, 1983, Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy., Ann Intern Med, 99, 745, 10.7326/0003-4819-99-6-745

Lal, 2008, Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients., Cancer Sci, 99, 816, 10.1111/j.1349-7006.2008.00744.x

Jeong, 2007, Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay., PLoS Genet, 3, e39, 10.1371/journal.pgen.0030039

Conrad, 2001, Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution., J Hum Genet, 46, 656, 10.1007/s100380170017

Conrad, 2002, A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance., Pharmacogenetics, 12, 321, 10.1097/00008571-200206000-00008

Yin, 2009, Characterization and analyses of multidrug resistance-associated protein 1 (MRP1ABCC1) polymorphisms in Chinese population., Pharmacogenet Genomics, 19, 206, 10.1097/FPC.0b013e328323f680

Rajic, 2009, Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood., Leuk Lymphoma, 50, 1693, 10.1080/10428190903177212

Bains, 2009, Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in-vitro metabolism of daunorubicin and doxorubicin., Drug Metab Dispos, 37, 1107, 10.1124/dmd.108.024711

Lal, 2008, CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients., Cancer Sci, 99, 2045, 10.1111/j.1349-7006.2008.00744.x

Gonzalez-Covarrubias, 2009, Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors., Drug Metab Dispos, 37, 400, 10.1124/dmd.108.024547

Fan, 2008, Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity., Pharmacogenet Genomics, 18, 621, 10.1097/FPC.0b013e328301a869

Bains, 2010, Naturally occurring variants of human CBR3 alter anthracycline in-vitro metabolism., J Pharmacol Exp Ther, 332, 755, 10.1124/jpet.109.160614

Blanco, 2008, Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene, NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer., Cancer, 112, 2789, 10.1002/cncr.23534

Lakhman, 2005, Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3)., Drug Metab Dispos, 33, 254, 10.1124/dmd.104.002006

Choi, 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res, 15, 5258, 10.1158/1078-0432.CCR-09-0685

Ross, 2004, NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics., Methods Enzymol, 382, 115, 10.1016/S0076-6879(04)82008-1

Sandanaraj, 2008, PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients., Clin Cancer Res, 14, 7116, 10.1158/1078-0432.CCR-08-0411

Lal, 2007, Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients., Pharmacogenomics, 8, 567, 10.2217/14622416.8.6.567

Bains, 2010, Naturally occurring variants of human CBR3 alter anthracycline in-vitro metabolism., J Pharmacol Exp Ther, 332, 755, 10.1124/jpet.109.160614